Affiblot screening device for antibody selection

Technology description

Export PDF

The name of the technology:	Affiblot screening device for antibody selection
Challenge:	The increasing use of antibodies in various research fields (e.g. biotechnology) is closely related to their ever-expanding market portfolio. Thus, the selection of a suitable commercial antibody for a given application, which has appropriate affinity, high specificity, reproducibility, and low cross-reactivity, becomes crucial for this research area. A certain part of antibodies on the market does not fulfill the mentioned criteria therefore it is recommended to test the antibody before starting the experiments with them.
Description:	- Compact device based on standard procedure dot blot technology - Innovative lid with reagent reservoirs on the upper side and a pattern of drainage microchannels on the bottom side ensure all steps are inside the device - Comparison of antibodies from multiple perspectives without cutting the membrane (against dot blot) - Parallel evaluation of up to 5 antibodies - Affinity/avidity comparison - Determination of cross-reactivity with other biomolecules and whole cells (e.g. bacterial) - Batch-to-batch comparison Advantages of the technology: - Only smartphone, vacuum pump, and software for densitometric evaluation are needed - Speed of assay and reproducibility - Simplicity in interpretation - Antigen applied to the membrane can be both soluble (protein/peptide) and corpuscular (e.g. bacterial cell) - Easy application, disposal of reagents, and blotting membrane - Easy, reproducible, and precise SLA 3D printing of device - Patented solution - reduction of time-consuming steps used in standard methods such as ELISA or Western blot
Commercial opportunity:	The end users are all research teams and laboratories that work with antibodies or other affinity reagents.
IP protection status:	Czech patent granted, doc. No. 308111 European patent granted, doc. No. 3669983
Development status:	Phase 2 Corresponds with TRL 3 and TRL 4 Feasibility study. There is a realistic design of the technology and the initial tests in the laboratory are leading to the specification of the technology requirements and its capabilities. TRL 3 represents a complete idea of a technology with the design of concrete steps, tests and experiments that will need to be carried out to verify that the idea is realistic TRL 4 is a verification of functionality in the laboratory. The result of TRL 4 is the so-called Proof-of-Concept. Technology is therefore designed and tested for its functionality under limited conditions
Partnering strategy:	Co-development Collaboration licensing
More information:	More information about the technology is provided in the publication: Affiblot: a dot blot-based screening device for selection of reliable antibodies (Anal. Methods, 2021, 13, 3874-3884). Use the QR code to download.
Images:
Categories:	Research Tools Diagnostics Life Science and Health Chemistry
Owner of a technology:	Univerzita Pardubice, Ústav analytické chemie AV ČR Brno